Biomechanics of suprachoroidal drug delivery: From benchtop to clinical investigation in ocular therapies

References

• Thorne JE, Sugar EA, Holbrook JT, et al. Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmology. 2019;126(2):283–295.
   PubMed Web of Science ®Google Scholar
• Hartman RR, Kompella UB. Intravitreal, subretinal, and suprachoroidal injections: evolution of microneedles for drug delivery. J Ocul Pharmacol Ther. 2018;34(1–2):141–153.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Wykoff CC, Brown DM, et al. Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study. Ophthalmol Retina. 2018 Apr;2(4):320–328.
   PubMedGoogle Scholar
• Chen M, Li X, Liu J, et al. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. J Control Release. 2015;203:109–117.
   PubMed Web of Science ®Google Scholar
• Chiang B, Jung JH, Prausnitz MR. The suprachoroidal space as a route of administration to the posterior segment of the eye. Adv Drug Deliv Rev. 2018 Feb;15(126):58–66.
   Web of Science ®Google Scholar
• Wykoff CC, Khurana RN, Lampen SIR, et al. Suprachoroidal triamcinolone acetonide for diabetic macular edema: the HULK trial. Ophthalmol Retina. 2018 Aug;2(8):874–877.
   PubMedGoogle Scholar
• Yeh S, Khurana RN, Shah M, et al. Efficacy and Safety of Suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology. 2020;127(7):948–955.
   PubMed Web of Science ®Google Scholar
• Moisseiev E, Loewenstein A, Yiu G. The suprachoroidal space: from potential space to a space with potential. Clin Ophthalmol. 2016;10:173–178.
   PubMed Web of Science ®Google Scholar
• Rai Udo J, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015 Apr;20(4):491–495.
   PubMed Web of Science ®Google Scholar
• Habot‐Wilner Z, Noronha G, Wykoff CC. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmologica. 2019 Aug;97(5):460–472.
   PubMed Web of Science ®Google Scholar
• Jung JH, Chae JJ, Prausnitz MR. Targeting drug delivery within the suprachoroidal space. Drug Discovery Today. 2019 Aug;24(8):1654–1659.
   PubMed Web of Science ®Google Scholar
• Pearce W, Hsu J, Yeh S. Advances in drug delivery to the posterior segment. Current Opinion in Ophthalmology. 2015 May;26(3):233–239.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Do D, Noronha G, et al. Suprachoroidal corticosteroid administration: a novel route for local treatment of noninfectious uveitis. Transl Vision Sci Technol. 2016 Dec;5(6):14.
   PubMed Web of Science ®Google Scholar
• Olsen TW, Feng X, Wabner K, et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol. 2019 Nov;97(5):460–472.
   Web of Science ®Google Scholar
• Peden MC, Min J, Meyers C, et al. Ab-externo AAV-mediated gene delivery to the suprachoroidal space using a 250 micron flexible microcatheter. PLoS One. 2011;6(2):e17140.
   PubMed Web of Science ®Google Scholar
• Yeh S, Kurup SK, Wang RC, et al. suprachoroidal injection of triamcinolone acetonide, cls-ta, for macular edema due to noninfectious uveitis: a randomized, Phase 2 Study (DOGWOOD). Retina. 2019;39(10):1880–1888.
   PubMed Web of Science ®Google Scholar
• Worthington KS, Wiley LA, Bartlett AM, et al. Mechanical properties of murine and porcine ocular tissues in compression. Exp Eye Res. 2014;121:194–199.
   PubMed Web of Science ®Google Scholar
• Krohn J, Bertelsen T. Light microscopy of uveoscleral drainage routes after gelatine injections into the suprachoroidal space. Acta Ophthalmol Scand. 1998 Oct;76(5):521–527.
   PubMedGoogle Scholar
• Vurgese S, Panda-Jonas S, Jonas JB. Scleral thickness in human eyes. PLoS One. 2012;7(1):e29692.
   PubMed Web of Science ®Google Scholar
• Olsen TW, Aaberg SY, Geroski DH, et al. Human sclera: thickness and surface area. Am J Ophthalmol. 1998 Feb;125(2):237–241.
   PubMed Web of Science ®Google Scholar
• Oliveira C, Tello C, Liebmann J, et al. Central corneal thickness is not related to anterior scleral thickness or axial length. J Glaucoma. 2006 Jun;15(3):190–194.
   PubMed Web of Science ®Google Scholar
• Norman RE, Flanagan JG, Rausch SM, et al. Dimensions of the human sclera: thickness measurement and regional changes with axial length. Exp Eye Res. 2010 Feb;90(2):277–284.
   PubMed Web of Science ®Google Scholar
• Patel SR, Berezovsky DE, McCarey BE, et al. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci. 2012;53(8):4433–4441.
   PubMed Web of Science ®Google Scholar
• Emi K, Pederson JE, Toris CB. Hydrostatic pressure of the suprachoroidal space. Invest Ophthalmol Vis Sci. 1989 Feb;30(2):233–238.
   PubMed Web of Science ®Google Scholar
• Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res. 2010 Mar;29(2):144–168.
   PubMed Web of Science ®Google Scholar
• Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res. 2010 Aug;11(2):14.
   Google Scholar
• Chiang B, Kim YC, Edelhauser HF, et al. Circumferential flow of particles in the suprachoroidal space is impeded by the posterior ciliary arteries. Exp Eye Res. 2016;145:424–431.
   PubMed Web of Science ®Google Scholar
• Krohn J, Bertelsen T. Corrosion casts of the suprachoroidal space and uveoscleral drainage routes in the human eye. Acta Ophthalmol Scand. 1997 Feb;75(1):32–35.
   PubMedGoogle Scholar
• Patel SR, Lin AS, Edelhauser HF, et al. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res. 2011 Jan;28(1):166–176.
   PubMed Web of Science ®Google Scholar
• Ding K, Shen J, Hafiz Z, et al. AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. J Clin Invest. 2019;129(11):4901–4911.
   PubMed Web of Science ®Google Scholar
• Shen J, Kim J, Tzeng SY, et al. Suprachoroidal gene transfer with nonviral nanoparticles. Sci Adv. 2020;6(27):eaba1606.
   PubMed Web of Science ®Google Scholar
• Kansara V, Muya L, Wan CR, et al. Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases. J Ocul Pharmacol Ther. 2020;36(6):384–392.
   PubMed Web of Science ®Google Scholar
• Henry CR, Schefler AC, Wan CR, et al. Post Hoc Analysis of Clinical Suprachoroidal Injection Experience Across Retinal Disease Indications Retina Society Annual Meeting 2020. [cited 2020 Oct 22]. Available from: https://www.clearsidebio.com/pdf/2020/henry-christopher-post-hoc-analysis.pdf
   Google Scholar
• Fisher N, Wan C. Suprachoroidal delivery with the SCS Microinjector™: characterization of Operational Forces. Invest Ophthalmol Vis Sci. 2020;61(7):24.
   Web of Science ®Google Scholar
• Fisher N, Yoo J, Hancock SE, et al. A Novel Technique to Characterize Key Fluid Mechanic Properties of the Suprachoroidal Injection Procedure in an In Vivo Model Association for Research in Vision and Ophthalmology Annual Meeting 2018. [cited 2020 Oct 28]. Available from: https://www.clearsidebio.com/?articleattachment=49
   Google Scholar
• Chiang B, Venugopal N, Grossniklaus HE, et al. Thickness and closure kinetics of the suprachoroidal space following microneedle injection of liquid formulations. Invest Ophthalmol Vis Sci. 2017;58(1):555–564.
   PubMed Web of Science ®Google Scholar
• Savinainen A, Grossniklaus H, Kang S, et al. Ocular distribution and efficacy after suprachoroidal injection of AU-011 for treatment of ocular melanoma. Invest Ophthalmol Vis Sci. 2020;61(7):3615.
   Web of Science ®Google Scholar
• Nork TM, Katz AW, Kim CBY, et al. Distribution of aqueous solutions injected suprachoroidally (SC) in rabbits. Invest Ophthalmol Vis Sci. 2020;61(7):320.
   Web of Science ®Google Scholar
• Oshika T, Bissen-Miyajima H, Fujita Y, et al. Prospective randomized comparison of DisCoVisc and Healon5 in phacoemulsification and intraocular lens implantation. Eye. 2010;24(8):1376–1381.
   PubMed Web of Science ®Google Scholar
• Kim YC, Oh KH, Edelhauser HF, et al. Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles. Eur J Pharm Biopharm. 2015 Sep;95(Pt B):398–406.
   PubMed Web of Science ®Google Scholar
• Chiang B, Venugopal N, Edelhauser HF, et al. Distribution of particles, small molecules and polymeric formulation excipients in the suprachoroidal space after microneedle injection. Exp Eye Res. 2016;153:101–109.
   PubMed Web of Science ®Google Scholar
• Hackett SF, Fu J, Kim YC, et al. Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularization. Biomaterials. 2020;243:119935.
   PubMed Web of Science ®Google Scholar
• Chiang B, Wang K, Ethier CR, et al. Clearance kinetics and clearance routes of molecules from the suprachoroidal space after microneedle injection. Invest Ophthalmol Vis Sci. 2017;58(1):545–554.
   PubMed Web of Science ®Google Scholar
• Mustafa MB, Tipton DL, Barkley MD, et al. Dye diffusion in isotropic and liquid-crystalline aqueous (hydroxypropyl)cellulose. Macromolecules. 1993;26(2):370–378.
   Web of Science ®Google Scholar
• FITC-Dextran Fluorescein isothiocyanate dextran. 2011.
   Google Scholar
• Jung JH, Desit P, Prausnitz MR. Targeted drug delivery in the suprachoroidal space by swollen hydrogel pushing. Invest Ophthalmol Vis Sci. 2018;59(5):2069–2079.
   PubMed Web of Science ®Google Scholar
• Jung JH, Chiang B, Grossniklaus HE, et al. Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle. J Control Release. 2018 May;10(277):14–22.
   Web of Science ®Google Scholar
• Touchard E, Berdugo M, Bigey P, et al. Suprachoroidal electrotransfer: a nonviral gene delivery method to transfect the choroid and the retina without detaching the retina. Mol Ther. 2012;20(8):1559–1570.
   PubMed Web of Science ®Google Scholar
• Edelhauser HF, Verhoeven RS, Burke B, et al. Intraocular distribution and targeting of triamcinolone acetonide suspension administered into the suprachoroidal space. Invest Ophthalmol Vis Sci. 2014;55(13):5259.
   Web of Science ®Google Scholar
• Hancock SE, Phadke A, Kansara V, et al. Ocular pharmacokinetics and safety of suprachoroidal A01017, small molecule complement inhibitor, injectable suspension in rabbits. Invest Ophthalmol Vis Sci. 2020;61(7):3694.
   Web of Science ®Google Scholar
• Kaiser PK, Ciulla T, Kansara V. Suprachoroidal CLS-AX (axitinib injectable suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD). Invest Ophthalmol Vis Sci. 2020;61(7):3977.
   Google Scholar
• Singer MA IOP Following Administration of Suprachoroidal Triamcinolone Acetonide Suspension (CLS-TA): Results from the Phase 3 PEACHTREE Clinical Trial for Uveitis Macula Society Annual Meeting 2020[cited 2020 Oct 12]. Available from: https://www.clearsidebio.com/?articleattachment=83
   Google Scholar
• Merrill P. Suprachoroidally Injected CLS-TA in Uveitis Maintains Efficacy Outcomes Through 48 Weeks: Results of the MAGNOLIA Phase 3 Extension Study American Society of Retina Specialists Annual Meeting 2019[cited 2020 Oct 12]. Available from: https://www.clearsidebio.com/?articleattachment=64
   Google Scholar
• Lampen SIR, Khurana RN, Noronha G, et al. Suprachoroidal space alterations following delivery of triamcinolone acetonide: post-hoc analysis of the Phase 1/2 HULK Study of patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2018;49(9):692–697.
   PubMed Web of Science ®Google Scholar
• Barakat M, Wan C, Kapik B. Post hoc analysis of clinical suprachoroidal injection experience across indications. Invest Ophthalmol Vis Sci. 2020;61(7):4954.
   Web of Science ®Google Scholar
• Wan C-R, Kapik B, Wykoff CC, et al. Clinical characterization of suprachoroidal injection procedure utilizing a microinjector across three retinal disorders. Trans Vision Sci Technol. 2020;9(11):27.
   PubMed Web of Science ®Google Scholar
• Lee JW, Park H, Choi JH, et al. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC Ophthalmol. 2016 May;31(16):69.
   Web of Science ®Google Scholar
• Lowder C, Belfort R Jr., Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011 May;129(5):545–553.
   PubMed Web of Science ®Google Scholar
• Shiroma HF, Takaschima AKK, Farah ME, et al. Patient pain during intravitreal injections under topical anesthesia: a systematic review. Int J Retina Vitreous. 2017;3:23.
   PubMedGoogle Scholar
• EYLEA (aflibcercept) [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2019.
   Google Scholar
• LUCENTIS (ranibizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc; 2018.
   Google Scholar
• Doguizi S, Sekeroglu MA, Inanc M, et al. Evaluation of pain during intravitreal aflibercept injections. Eur J Ophthalmol. 2018 Jan;28(1):63–67.
   PubMed Web of Science ®Google Scholar
• Yeh S Suprachoroidally Injected CLS-TA Improves Visual Acuity and Macular Edema in Noninfectious Uveitis: Results of the Phase 3 PEACHTREE Study American Society of Retina Specialists Annual Meeting 2018. [cited 2020 Oct 28]. Available from: https://www.clearsidebio.com/Yeh__S._Suprachoroidally_Injected_CLS-TA_Improves_Visual_Acuity_and_Macular_Edema_in_Noninfectious_Uveities_Results_of_the_Phase_3_PEACHTREE_Study.pdf
   Google Scholar
• Regenxbio Reports First Quarter 2020. Financial Results and Operational HighlightsNews Releases. Rockville, MD: REGENXBIO, 2020. [cited 2020 Dec 23]. Available from: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-reports-first-quarter-2020-financial-results-and
   Google Scholar
• Aura Biosciences Presents Updated AU-011 Clinical Data at ARVO 2020.Press Releases. Cambridge, MA: Aura Biosciences, 2020. [cited 2020 Dec 23]. Available from: http://www.aurabiosciences.com/news-archive/2020/6/12/aura-biosciences-presents-updated-au-011-clinical-data-at-arvo–2020
   Google Scholar